CTRP Terminology
CTRP Agent Terminology
NCIt Antineoplastic Agent Terminology
GDC Terminology
GDC Therapeutic Agent Terminology
NCI Drug Dictionary Terminology
GDC Value Terminology
Selective Estrogen Receptor Modulator
Pharmacologic Substance
Estrogen Receptor
FDA Established Names and Unique Ingredient Identifier Codes Terminology
Endoxifen Hydrochloride
1032008-74-4
308PA1L567
4-Hydroxy-N-Desmethyltamoxifen Hydrochloride
693335
693335
693335
C95713
CL428178
CTRP
ENDOXIFEN HYDROCHLORIDE
Endoxifen Hydrochloride
Endoxifen Hydrochloride
Endoxifen Hydrochloride
FDA
GDC
Pharmacologic Substance
The hydrochloride salt and the z (cis-) stereoisomer of endoxifen with potential antineoplastic activity. Endoxifen, the active metabolite of tamoxifen, competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA and thus reducing DNA synthesis. Unlike tamoxifen, however, which relies on CYP2D6 activity for its conversion to the active metabolite endoxifen, the direct administration of endoxifen bypasses the CYP2D6 route. As CYP2D6 activity can vary widely among individuals due to genetic CYP2D6 polymorphisms, endoxifen is therefore theoretically more potent and more uniform in its bioavailability across patient populations.
Z-Endoxifen HCl
Z-Endoxifen Hydrochloride
Z-Endoxifen Hydrochloride